115 related articles for article (PubMed ID: 10463078)
1. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.
Irie A; Anderegg B; Kashani-Sabet M; Ohkawa T; Suzuki T; Halks-Miller M; Curiel DT; Scanlon KJ
Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):341-9. PubMed ID: 10463078
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
[TBL] [Abstract][Full Text] [Related]
3. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line.
Eastham JA; Ahlering TE
J Urol; 1996 Sep; 156(3):1186-8. PubMed ID: 8709343
[TBL] [Abstract][Full Text] [Related]
4. Hammerhead ribozymes as therapeutic agents for bladder cancer.
Irie A; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
Mol Urol; 2000; 4(2):61-6. PubMed ID: 12006244
[TBL] [Abstract][Full Text] [Related]
5. Reversal of the malignant phenotype by an anti-ras ribozyme.
Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
[TBL] [Abstract][Full Text] [Related]
6. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer.
Kijima H; Yamazaki H; Nakamura M; Scanlon KJ; Osamura RY; Ueyama Y
Int J Oncol; 2004 Mar; 24(3):559-64. PubMed ID: 14767540
[TBL] [Abstract][Full Text] [Related]
7. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma.
Tsuchida T; Kijima H; Hori S; Oshika Y; Tokunaga T; Kawai K; Yamazaki H; Ueyama Y; Scanlon KJ; Tamaoki N; Nakamura M
Cancer Gene Ther; 2000 Mar; 7(3):373-83. PubMed ID: 10766343
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.
Irie A; Matsumoto K; Anderegg B; Kuruma H; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
Cancer Gene Ther; 2006 Mar; 13(3):298-305. PubMed ID: 16110311
[TBL] [Abstract][Full Text] [Related]
10. Suppression of EJ cells tumorigenicity.
Tone T; Kashani-Sabet M; Funato T; Shitara T; Yoshida E; Kashfian BI; Horng M; Fodstadt O; Scanlon KJ
In Vivo; 1993; 7(6A):471-6. PubMed ID: 8193263
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells.
Suzuki T; Anderegg B; Ohkawa T; Irie A; Engebraaten O; Halks-Miller M; Holm PS; Curiel DT; Kashani-Sabet M; Scanlon KJ
Gene Ther; 2000 Feb; 7(3):241-8. PubMed ID: 10694801
[TBL] [Abstract][Full Text] [Related]
12. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
[TBL] [Abstract][Full Text] [Related]
13. Ribozyme as an approach for growth suppression of human pancreatic cancer.
Kijima H; Scanlon KJ
Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
[TBL] [Abstract][Full Text] [Related]
14. Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways.
Wang CH; Tsai LJ; Tsao YP; Hsieh JT; Chien WW; Liao CL; Wang HW; Liu HS; Chen SL
Biochem Biophys Res Commun; 2002 Nov; 298(5):805-14. PubMed ID: 12419327
[TBL] [Abstract][Full Text] [Related]
15. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant.
Watanabe T; Shinohara N; Sazawa A; Takimoto M; Hashimoto A; Koyanagi T; Kuzumaki N
Int J Cancer; 2001 Jun; 92(5):712-7. PubMed ID: 11340577
[TBL] [Abstract][Full Text] [Related]
17. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
[TBL] [Abstract][Full Text] [Related]
18. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA.
Nakano M; Aoki K; Matsumoto N; Ohnami S; Hatanaka K; Hibi T; Terada M; Yoshida T
Mol Ther; 2001 Apr; 3(4):491-9. PubMed ID: 11319909
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer.
Miceli C; Tejada A; Castaneda A; Mistry SJ
Cancer Gene Ther; 2013 May; 20(5):298-307. PubMed ID: 23618950
[TBL] [Abstract][Full Text] [Related]
20. [Adenovirus-mediated transfer of anti-MDR1 ribozyme in the treatment of multidrug-resistant human lymphoma in SCID mice].
Xu D; Wang F; Ohnuma T; Jin L
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):529-32. PubMed ID: 12667317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
